The record
Written from the 1 report below. Nothing here is unsourced.
- A dengue vaccine named QDENGA, developed by Takeda, has received marketing authorization from the Central Drugs Standard Control Organization in India.
- The vaccine will be distributed through a partnership with Dr.
- Reddy's Laboratories and is approved for individuals aged 4 to 60.
- It requires two doses administered three months apart and is designed to protect against all four strains of the dengue virus.
What to watch next
- Actual availability of the vaccine in the Indian market
- Ongoing preventive measures against mosquito bites
Who said what1
Only words found exactly in the article are shown, attributed and linked to the line they came from.
Jugal Kishore
1 quote · 1 outlet
“वैक्सीन आने से काफी फायदा होगा, हालांकि वैक्सीन उपलब्ध होने के बाद भी मच्छरों से बचाव जरूरी रखना होगा.”
In the article
…है? इस वैक्सीन के बारे में महामारी विशेषज्ञ डॉ जुगल किशोर ने बताया कि कई सालों से इस वैक्सीन को बनाने का काम चल रहा था. इसको सेंट्रल ड्रग्स स्टैंडर्ड कंट्रोल ऑर्गनाइजेशन (CDSCO) से मार्केटिंग अथॉराइजेशन मिल गया था. वैक्सीन आने से काफी फायदा होगा, हालांकि वैक्सीन उपलब्ध होने के बाद भी मच्छरों से बचाव जरूरी रखना होगा.
Coverage1
1 report
Indian-language1
All filed from India
Named India · Central Drugs Standard Control Organization · Dr Reddy's Laboratories · Jugal Kishore · Takeda
The 1 report is listed beside the record.
Ask this story
Answers cite the reports above, or say they can't.